Lubna Chaudhary
Medical College of Wisconsin
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Lubna Chaudhary as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:35 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07643428 · Cancer Lipidome Adaptation and Resculping Through Omega-3 PUFAs in Breast TumorsMedical College of Wisconsin · not yet recruiting · Breast Cancer · principal investigator
- Ph2NCT04243616 · Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast CancerMedical College of Wisconsin · active not recruiting · Invasive Breast Cancer · principal investigator
- Ph2NCT03219476 · Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast CancerMedical College of Wisconsin · completed · Breast Cancer, Invasive Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Quantitative Analyses of HER2 Upregulation in Luminal Breast Cancer in Response to Neoadjuvant Endocrine TherapyR03CA259594 · NCI · MEDICAL COLLEGE OF WISCONSIN · fiscal years 2021 to 2022 · $81,220 awarded in 2022Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:35 UTC. The ranking covers the 200 most relevant of 1 PubMed records, and a shared surname and initials can bring in a namesake. All 1 on PubMed
- A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.Clin Breast Cancer · 20254 citationsRCR 1.1